Merck & Co., Inc. Equity Securities without Readily Determinable Fair Value, Amount
Merck & Co., Inc. (MRK) had Equity Securities without Readily Determinable Fair Value, Amount of $851.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount · last filed 2026-08-07
- 2026-06-30: Equity Securities without Readily Determinable Fair Value, Amount $851.00M.
- 2026-03-31: Equity Securities without Readily Determinable Fair Value, Amount $881.00M.
- 2025-12-31: Equity Securities without Readily Determinable Fair Value, Amount $831.00M.
- 2025-09-30: Equity Securities without Readily Determinable Fair Value, Amount $834.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Amount |
|---|---|
| 2026-06-30 | $851.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $881.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $831.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $834.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $870.00M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $872.00M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $863.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $848.00M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $936.00M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $851.00M 10-Q · filed 2025-05-02 |
| 2023-12-31 | $832.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $863.00M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $949.00M 10-Q · filed 2024-08-05 |
| 2023-03-31 | $942.00M 10-Q · filed 2024-05-03 |
| 2022-12-31 | $832.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | $705.00M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $671.00M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $643.00M 10-Q · filed 2023-05-05 |
| 2021-12-31 | $596.00M 10-K · filed 2023-02-24 |
| 2021-09-30 | $578.00M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $694.00M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $651.00M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $586.00M 10-K · filed 2022-02-25 |
| 2020-09-30 | $508.00M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $487.00M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $450.00M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $420.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $393.00M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $465.00M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $542.00M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $568.00M 10-K · filed 2020-02-26 |
| 2018-09-30 | $749.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $675.00M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |